1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2026

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2026

  • June 2017
  • 203 pages
  • ID: 4263107
  • Format: PDF
  • By GlobalData

Summary

Table of Contents

Search Inside

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2026

Summary
Venous thromboembolism (VTE) is a disease that includes a myriad of life-threatening disorders ranging from pulmonary embolism (PE) to deep vein thrombosis (DVT). The therapeutic landscape for VTE is divided into the VTE treatment setting and VTE primary prophylaxis, which is further divided into the prophylaxis for total knee replacement (TKR) and total hip replacement (THR) patients, as well as for acute medically ill patients. Antithrombotic therapy represents the cornerstone treatment strategy for all VTE patients. Presently, the established vitamin K antagonists (VKA) and low molecular weight heparins (LMWH) are the most widely prescribed drugs for VTE treatment and prophylaxis, where the historical dominance of these therapies has been the most prominent barrier towards VTE market evolution and growth.

It is estimated that sales of venous thromboembolism (VTE) therapeutics were approximately $1.95B across the seven major markets (7MM) in 2016, which includes the US, the five major European markets (5EU: France, Germany, Italy, Spain, and UK), and Japan. In the 2016 base year, 25% of market shares were attributed to the VTE treatment setting ($497M) and 75% to VTE primary prophylaxis treatments ($1.45B).

By 2026, it is expected that the VTE market to grow at a strong Compound Annual Growth Rate (CAGR) of 3.87%, reaching sales of $2.85B by the end of the forecast period. The main market contributing to the sustained growth over this forecast is the US, contributing $1.43B in sales in 2016, a figure that is anticipated to increase at a CAGR of 3.08% to $1.94B by 2026. Over this forecast, the most prominent wave of sales increases comes from the novel oral anticoagulant (NOAC) class, which is expected to peak at $1.04B in global sales by 2022, reflecting a 10-year CAGR of 3.91% by 2026, despite the generic erosion of several key players.

Major drivers of VTE market growth over the forecast period are the -
- Increase in patient shares towards the NOACs due to increased confidence among physicians about using these novel therapies.
- Launch of betrixaban for extended-duration prophylaxis in acute medically ill patients.
- Launch of the first Factor XI inhibitor, IONIS-FXIRX.
- Increase in the global prevalence of VTE.
- Launch of the Factor Xa reversal agents.

Major growth in the VTE market over the forecast period is caused by the rise in sales surrounding the VTE primary prophylaxis space, which increased from $1.45B in 2016 to $2.3B by 2026 at a CAGR of 4.66%. The VTE prophylaxis segment dominates the VTE space due to the much higher number of patients in need of prophylaxis compared to the number of patients in need of VTE treatment.

The report "PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2026" provides an Overview of VTE, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

In depth, this report provides the following -
- Annualized VTE therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the VTE therapeutics market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global VTE therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Companies mentioned in this report: Boehringer Ingelheim, Bayer, Janssen, BMS, Pfizer, Sanofi, Daiichi-Sankyo, Portola Pharmaceuticals, Ionis Therapeutics, Armetheon.

Scope
- Overview of VTE, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Annualized VTE therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the VTE therapeutics market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global VTE therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
- Develop business strategies by understanding the trends shaping and driving the global VTE therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global VTE therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global VTE therapeutics market from 2016-2026.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
30% Off

($10995)

  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Kidney Transplant Rejection - Pipeline Review, H2 2019

Kidney Transplant Rejection - Pipeline Review, H2 2019

  • $ 2000
  • December 2019

Kidney Transplant Rejection - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Kidney Transplant Rejection - Pipeline Review, H2 2019, provides an overview ...

Bacteremia Global Clinical Trials Review, H2, 2019

Bacteremia Global Clinical Trials Review, H2, 2019

  • $ 2500
  • December 2019

Bacteremia Global Clinical Trials Review, H2, 2019Summaryclinical trial report, “Bacteremia Global Clinical Trials Review, H2, 2019" provides an overview of Bacteremia clinical trials scenario.This report ...

Ablation Equipments - Medical Devices Pipeline Assessment, 2020

Ablation Equipments - Medical Devices Pipeline Assessment, 2020

  • $ 4000
  • February 2020

Ablation Equipments - Medical Devices Pipeline Assessment, 2020SummaryMedical Devices sector report, “Ablation Equipments - Medical Devices Pipeline Assessment, 2020" provides an overview of Ablation ...

Wounds - Pipeline Review, H2 2019 $ 2000 December 2019


ref:plp2017

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on